Dania Maimouni

Quantifying the impact of decarbonization incentives and requirements of specific IRA provisions to build a clean fuels and electrification strategy Predicting the policy landscape in US healthcare to anticipate major changes impacting its markets Creating a strategy for the company to best position itself for future contracting opportunities in the security screening and logistics https://www.inrecognition.org/can-augmented-reality-create-new-business-opportunities/ space Predicting the policy and regulatory environment surrounding airport security with respect to inbound logistics to airport terminals Quantifying the impact that federal funding and the restructuring of Puerto Rico’s debt obligations would have on Gross Domestic Product and read throughs to the local economy

Creating a strategy to underscore the company’s funding opportunities and expansion potential in favorable states Capstone created a fan of outcomes for potential changes in contracting dynamics among national, regional, and “blues” payors with VBC partners to understand the potential risks or opportunities for provider partners over the next 5 years. Creating a strategy identifying major risks and opportunities for this business to navigate DOGE-era contracting volatility and to inform our private equity client’s investment strategy. Predicting the policy landscape impacting a US business with operations and staff in Ukraine and Belarus, including specific sanctions exposure and other business interruption risk. PD-L1 inhibitors have demonstrated survival benefits for patients with extensive-stage small cell lung cancer (ES-SCLC); however, consensus remains limited regarding which specific inhibitor offers the best clinical outcomes. Dr. Sands shared insights on the ongoing Alliance Foundation trial (AFT-61) that explores the addition of immunotherapy, specifically durvalumab, in patients with potentially resectable small cell lung cancer.

Creating a strategy for our private equity client to navigate the DoD’s fragmented cyber acquisition community and provided key https://business-soulwork.com/what-techniques-increase-customer-engagement/ insights to help an early-stage cyber company cross the “valley of death” onto funded programs of record. Quantifying the impact of the DoD’s realignment of cyber authorities and organizations, which could reshape funding across the entire cyber enterprise.​ Predicting the policy landscape for an enduring cybersecurity training requirements across the military services asthe DoD centralizes cybersecurity authorities.

Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study

Quantifying the impact of sanctions and export controls that would prevent the company from operating in specific regions This included assessing perspectives on the value and utilization growth of personal care services and levers available to both the state and payors to potentially limit/encourage growth. Specifically, we analyzed the outlook for changes in operations by other operators in the OTP ecosystems, including pharmacies, OTP take-home prescription practices, and pharmaceutical manufacturers participating with the new channel. This included an in-depth analysis of the NIH grant lifecycle, history of PDUFA legislation, and outlook for NIH funding disruptions to the pre-clinical timeline. Quantifying the impact of major initiatives across the Combatant Commands, which we identified as an underappreciated source of funding for non-platform ISR systems.

• Creating a strategy to highlight the company’s expansion opportunities in the most favorable biofuel markets
• Predicting the policy and regulatory environment around the commercialization of dual-use defense technology and assess federal and state-level demand for wildfire-fighting intelligence services.​
• Predicting the policy and regulatory environment of impacting the utilization of drones for operations over people and moving vehicles, which necessitates interpretation of vague FAA regulations.​
• Quantifying the impact of CHIPS Act funding on the manufacturer’s R&D initiatives and other operations
• Quantifying the impact of current and future banking sanctions, export controls, and reputational risk on business operations and the overall attractiveness of the Company.
• Predicting the policy and regulatory environment impacting a provider of natural disaster risk modeling for governments, utility and insurance markets.​

Sixty-three patients were excluded due to loss to follow-up. To adjust for potential confounding factors, univariate Cox proportional hazards regression analyses were first performed. Patients who had not experienced disease progression or death at the time of analysis were censored at the date of their last available follow-up assessment. Follow-up ended on April 1, 2024, and the median duration of follow-up for all patients was 19.5 months (range, 4.3–47.6 months). All enrolled patients underwent regular outpatient reviews and telephone follow-ups after admission, with regular physical examinations and chest computed tomography (CT) during follow-up. OS was defined as the period from receiving the first dose of systemic therapy to death from any cause or the last day of follow-up.

SaaS Provider to the Department of Defense​

Predicting the policy landscape shaping the US market for rare earth magnets used in advance military weapons systems amid growing concern over rare earth supply chains.​ Predicting the policy and regulatory outlook inthe US and EU for navigation, flight planning, and operational planning tools utilized by the commercial, military, and general aviation industry. Quantifying the impact of complying with FAA regulations on the operations of a business with extensive drone operations in areas that may be in regulatory grey areas. Creating a strategy for underwriting the contract risks to the business based on key known and unknowns in USTRANSCOM’s processes and our forward-looking views on how the risks are likely to materialize in years.

PFS was defined as the period from receiving the first dose of systemic therapy to disease progression, death from any cause, or the last day of follow-up. This research not only addresses a significant clinical question but also holds the potential to inform treatment protocols and influence future therapeutic developments in the field of oncology. Consequently, there is a pressing need for real-world data to ascertain the most effective immune checkpoint inhibitor for treating patients with small cell lung cancer (SCLC) in routine clinical settings. The current challenges in small-cell lung cancer treatment include identifying effective biomarkers, such as PD-L1 expression and tumor mutational burden, for accurate patient selection, which has proven insufficient so far11.